Suspension from Quotation
Released
Released
Announcement PDF
Market
Announcement
17 November 2026
17 November 2026 35 8.0 Market Announcement 1/1
#11170872v1
Microba Life Sciences Limited (ASX: MAP) –
Suspension from Quotation
The securities of Microba Life Sciences Limited (‘MAP’) will be suspended from quotation immediately
under Listing Rule 17.2 at the request of MAP, pending the release of an announcement by MAP.
Unless ASX decides otherwise, the securities will remain suspended until the earlier of:
• the end of the period stated in MAP’s request for voluntary suspension; or
• the release of the announcement to the market.
MAP’s request for voluntary suspension is attached below for the information of the market.
Issued by
ASX Supervision
1837 6.0
ASX Announcement
17 November 2026
JOIN MICROBA’S INTERACTIVE INVESTOR HUB
For more Company information and to engage with management by asking questions about Microba’s latest announcements
and updates, visit ir.microba.com/welcome
Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621
Ms Renee Hutchens
Adviser, ASX Listings Compliance (Sydney)
20 Bridge Street,
SYDNEY, NSW 2000
By email: tradinghaltssydney@asx.com.au
Request for Voluntary Suspension – Microba Life Sciences Ltd (ASX: MAP)
Microba Life Sciences Ltd (ASX: MAP) (Microba) requests a voluntary suspension of all its quoted securities to
apply from the commencement of trading on Tuesday, 17 November 2026.
At its request, Microba entered a trading halt on Friday, 13 November 2026, pending an announcement regarding
proposed material changes to the terms of the proposed merger between Microba and Genetic Signatures Ltd
(Proposed Merger).
Following discussions between Microba and Genetic Signatures Ltd, the revised indicative terms of the Proposed
Merger, while considered generally commercially acceptable to the Microba Board, are on terms such that
Microba will be unable to satisfy the conditions to complete Tranche 2 of the institutional placement, announced to
the ASX on 20 October 2026 (Placement).
The impact of the Placement not proceeding is that Microba will not have the financial capacity to complete the
Proposed Merger and will have a reduced cashflow runway. Microba is currently assessing its cashflow position
and is exploring its options for alternative funding (Stated Purpose). Until this has been determined, Microba
considers that continued trading in its securities is likely to be materially prejudicial to its ability to complete any
transaction critical to its continued financial viability.
In accordance with ASX Listing Rule 17.2, Microba provides the following information:
(a) Microba requests the voluntary suspension be put in place until the earlier of commencement of trading
on Monday, 23 November 2026 or such time that Microba makes an announcement to the market in
relation to the Stated Purpose above;
(b) Microba is not aware of any reason why the voluntary suspension should not be granted; and
(c) Microba is not aware of any other information necessary to inform the market about the voluntary
suspension.
Yours sincerely,
James Heath
CFO & Company Secretary
This announcement has been authorised for release by the Board of Directors.
For further information, please contact:
About Microba Life Sciences Limited
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools,
Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better
insights. Better health. Microba - Expect better. www.microba.com
Share your feedback
Discover